The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
- PMID: 17043764
- DOI: 10.1007/s10555-006-9004-4
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
Abstract
Interleukin-1 (IL-1) includes a family of closely related genes; the two major agonistic proteins, IL-1alpha and IL-1beta, are pleiotropic and affect mainly inflammation, immunity and hemopoiesis. The IL-1Ra antagonist is a physiological inhibitor of pre-formed IL-1. Recombinant IL-1alpha and IL-1beta bind to the same receptors and induce the same biological functions. As such, the IL-1 molecules have been considered identical in normal homeostasis and in disease. However, the IL-1 molecules differ in their compartmentalization within the producing cell or the microenvironment. Thus, IL-1beta is solely active in its secreted form, whereas IL-1alpha is mainly active in cell-associated forms (intracellular precursor and membrane-bound IL-1alpha) and only rarely as a secreted cytokine, as it is secreted only in a limited manner. IL-1 is abundant at tumor sites, where it may affect the process of carcinogenesis, tumor growth and invasiveness and also the patterns of tumor-host interactions. Here, we review the effects of microenvironment- and tumor cell-derived IL-1 on malignant processes in experimental tumor models and in cancer patients. We propose that membrane-associated IL-1alpha expressed on malignant cells stimulates anti-tumor immunity, while secretable IL-1beta, derived from the microenvironment or the malignant cells, activates inflammation that promotes invasiveness and also induces tumor-mediated suppression. Inhibition of the function of IL-1 by the IL-1Ra, reduces tumor invasiveness and alleviates tumor-mediated suppression, pointing to its feasibility in cancer therapy. Differential manipulation of IL-1alpha and IL-1beta in malignant cells or in the tumor's microenvironment can open new avenues for using IL-1 in cancer therapy.
Similar articles
-
Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions.Eur J Cancer. 2006 Apr;42(6):751-9. doi: 10.1016/j.ejca.2006.01.010. Epub 2006 Mar 10. Eur J Cancer. 2006. PMID: 16530403 Review.
-
Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?Immunol Rev. 2008 Apr;222:222-41. doi: 10.1111/j.1600-065X.2008.00615.x. Immunol Rev. 2008. PMID: 18364005 Review.
-
Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors.Cancer Res. 2007 Feb 1;67(3):1062-71. doi: 10.1158/0008-5472.CAN-06-2956. Cancer Res. 2007. PMID: 17283139
-
Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biology.Curr Pharm Des. 2017;23(32):4893-4905. doi: 10.2174/1381612823666170613080919. Curr Pharm Des. 2017. PMID: 28606052 Review.
-
Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells.J Immunol. 2009 Apr 15;182(8):4874-81. doi: 10.4049/jimmunol.0803916. J Immunol. 2009. PMID: 19342666
Cited by
-
Novel Dairy Fermentates Have Differential Effects on Key Immune Responses Associated with Viral Immunity and Inflammation in Dendritic Cells.Foods. 2024 Jul 29;13(15):2392. doi: 10.3390/foods13152392. Foods. 2024. PMID: 39123583 Free PMC article.
-
Dibutyltin-induced alterations of interleukin 1beta secretion from human immune cells.J Appl Toxicol. 2017 Feb;37(2):181-191. doi: 10.1002/jat.3339. Epub 2016 May 17. J Appl Toxicol. 2017. PMID: 27185338 Free PMC article.
-
DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer.Cancer Immunol Immunother. 2013 Feb;62(2):337-45. doi: 10.1007/s00262-012-1340-3. Epub 2012 Aug 26. Cancer Immunol Immunother. 2013. PMID: 22923190 Free PMC article.
-
Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility.World J Gastrointest Oncol. 2016 Jun 15;8(6):520-5. doi: 10.4251/wjgo.v8.i6.520. World J Gastrointest Oncol. 2016. PMID: 27326321 Free PMC article.
-
A comprehensive review on RNA interference-mediated targeting of interleukins and its potential therapeutic implications in colon cancer.3 Biotech. 2023 Jan;13(1):18. doi: 10.1007/s13205-022-03421-x. Epub 2022 Dec 20. 3 Biotech. 2023. PMID: 36568500 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials